In patients who need more advanced treatments for incontinence, we currently have the options of treating them through surgery or through the injection of bulking agents like collagen. Although collagen injections give good short-term results and are less invasive than surgery, there is a possibility of the collagen being reabsorbed or causing allergic reactions, said Ryan J. Pruchnic, of the departments of urology and orthopaedic surgery, University of Pittsburgh School of Medicine and lead author of the study. In our study, MDCs have the potential to offer a longer-term solution without the risk of rejection.
Pruchnic and colleagues presented these findings today at the Centennial Celebration Annual Meeting of the American Urological Association (AUA). Results are published in abstract 131 in the AUA proceedings.
In the study, researchers obtained a mixed population of MDCs from a mouse skeletal muscle biopsy. The cells were purified to obtain a population that was purely myogenic meaning that the cells were from muscle and capable of producing muscle. One cell from this population was then genetically engineered and cloned to form a large population. These cells were then injected into the bladder walls of mice.
The bladders of the mice were evaluated at one, four and eight weeks and 6 months. On evaluation, researchers noted the presence of myofibers, or differentiated muscle cells, throughout the smooth muscle layer, the number of which did not significantly decrease over time. Some of the myofibers expressed a-smooth muscle ac
'"/>
Contact: Jocelyn Uhl
412-647-3555
University of Pittsburgh Medical Center
25-May-2002